Почетна › Рак на простата › Тенеси
Клинички испитувања за Рак на простата во Тенеси
50 студии за Рак на простата бараат учесници на локации во Тенеси.
Градови во Тенеси
Официјален текст на студијата (англиски)
A Study of GSK5458514 Administered Alone or In Combination With Other Anti-Cancer Agents in Participants With Prostate Cancer
- GSK Investigational Site, Nashville
Се регрутираФаза 1/2
Возраст 18 и постари · Мажи · Ажурирано 5.10.2026 · NCT06990880A Study to Learn About the Investigational Drug Rinzimetostat (ORIC-944) in Patients With mCRPC Who Were Previously Treated With Abiraterone Acetate (Himalayas-1)
- Urology Associates, Nashville
Се регрутираФаза 3
Возраст 18 и постари · Мажи · Ажурирано 5.10.2026 · NCT07723248A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
- Sarah Cannon Research Institute, Nashville
- Tennessee Oncology PLLC, Nashville
Се регрутираФаза 1
Возраст 18 и постари · Сите полови · Ажурирано 2.10.2026 · NCT06465069The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- Sarah Cannon Research Institute, Nashville
Се регрутираФаза 1/2
Возраст 12 и постари · Сите полови · Ажурирано 2.10.2026 · NCT04585750A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
- SCRI Oncology Partners, Nashville
Се регрутираФаза 2
Возраст 18 и постари · Сите полови · Ажурирано 1.10.2026 · NCT06172478Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
- Vanderbilt University/Ingram Cancer Center, Nashville
Се регрутираФаза 2
Возраст 18 и постари · Сите полови · Ажурирано 30.9.2026 · NCT03866382A Study of JNJ-87189401 Combined With JNJ-78278343 for Advanced Prostate Cancer
- Tennessee Oncology, Nashville
Се регрутираФаза 1
Возраст 18 и постари · Мажи · Ажурирано 28.9.2026 · NCT06095089DESTINY-PANTUMOUR04
- Research Site, Nashville
Се регрутираНабљудувачка студија
Возраст од 18 до 130 · Сите полови · Ажурирано 25.9.2026 · NCT07124000Study of HLD-0915 (JNJ-101556143) in Patients With Metastatic Prostate Cancer
- Sarah Cannon Research Institute, Nashville
- Urology Associates, Nashville
Се регрутираФаза 1/2
Возраст 18 и постари · Мажи · Ажурирано 25.9.2026 · NCT06800313A Study of JNJ-101556143 in Participants With Metastatic Prostate Cancer
- The Conrad Pearson Clinic, Germantown
Се регрутираФаза 2
Возраст 18 и постари · Мажи · Ажурирано 25.9.2026 · NCT07832292A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
- The West Clinic, PLLC dba West Cancer Center ( Site 0063), Germantown
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 25.9.2026 · NCT06136650This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
- Tennessee Oncology, PLLC - Chattanooga Downtown, Chattanooga
- Tennessee Oncology PLLC, Chattanooga
- Tennessee Oncology, PLLC - Chattanooga Med Park II, Chattanooga
- и уште 20
Се регрутираФаза 3
Возраст 18 и постари · Мажи · Ажурирано 24.9.2026 · NCT07028853A Study in Patients With Metastatic Castration-Resistant Prostate Cancer
- Tennessee Oncology, Nashville
Се регрутираФаза 1
Возраст 18 и постари · Мажи · Ажурирано 24.9.2026 · NCT07719361A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
- Sarah Cannon Research Institute Oncology Partners, Nashville
- United States Oncology Regulatory Affairs Corporate Office, Nashville
Се регрутираФаза 3
Возраст 18 и постари · Мажи · Ажурирано 22.9.2026 · NCT07213674Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC
- Tennessee Oncology PLLC, Chattanooga
Се регрутираФаза 3
Возраст од 18 до 100 · Мажи · Ажурирано 22.9.2026 · NCT06855277A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation
- Research Site, Nashville
Се регрутираФаза 3
Возраст 18 и постари · Мажи · Ажурирано 18.9.2026 · NCT06952803Phase 1 Trial to Study JANX013 and JANX007 Combination in mCRPC
- Sarah Cannon Research Institute, Nashville
Се регрутираФаза 1
Возраст 18 и постари · Мажи · Ажурирано 17.9.2026 · NCT07813637High Dose Testosterone for ATM, CDK12 or CHEK2 Altered Prostate Cancers
- Memphis VA Medical Center, Memphis, TN, Memphis
- Tennessee Valley Healthcare System Nashville Campus, Nashville, TN, Nashville
Се регрутираФаза 2
Возраст 18 и постари · Мажи · Ажурирано 17.9.2026 · NCT05011383A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
- Memphis VA Medical Center ( Site 0072), Memphis
- SCRI Oncology Partners ( Site 0074), Nashville
- Henry-Joyce Cancer Clinic ( Site 0042), Nashville
Се регрутираФаза 3
Возраст 18 и постари · Мажи · Ажурирано 17.9.2026 · NCT06925737Trial of Xaluritamig in Adults With Metastatic Castration-resistant Prostate Cancer
- Sarah Cannon Research Institute Oncology Partners, Nashville
Се регрутираФаза 1
Возраст 18 и постари · Мажи · Ажурирано 15.9.2026 · NCT07493512Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy
- Urology Associates of Nashville, Nashville
Се регрутираФаза 3
Возраст 18 и постари · Мажи · Ажурирано 11.9.2026 · NCT06056830A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors
- Sarah Cannon Research Center, Nashville
Се регрутираФаза 1
Возраст 18 и постари · Сите полови · Ажурирано 9.9.2026 · NCT06440005A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Activity of GDC-1261 in Participants With Advanced or Metastatic Prostate Cancer
- Sarah Cannon Research Institute, Nashville
Се регрутираФаза 1/2
Возраст 18 и постари · Мажи · Ажурирано 4.9.2026 · NCT07567846A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer
- Tennessee Oncology Nashville, Nashville
Се регрутираФаза 2
Возраст 18 и постари · Мажи · Ажурирано 3.9.2026 · NCT07005154Study of JANX014 in Subjects With Metastatic Castration-Resistant Prostate Cancer
- SCRI Oncology Partners, Nashville
Се регрутираФаза 1
Возраст 18 и постари · Мажи · Ажурирано 3.9.2026 · NCT07545811AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)
- Research Site, Nashville
Се регрутираФаза 3
Возраст 18 и постари · Мажи · Ажурирано 26.8.2026 · NCT07611110Study of Oral MRT-2359 With Apalutamide in Prostate Cancer
- Sarah Cannon Research Institute, Nashville
Се регрутираФаза 2
Возраст 18 и постари · Мажи · Ажурирано 24.8.2026 · NCT07745361Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer
- United States Oncology Regulatory Affairs Corporate Office, Nashville
Се регрутираФаза 1
Возраст 18 и постари · Мажи · Ажурирано 21.8.2026 · NCT04221542FOG-001 in Locally Advanced or Metastatic Solid Tumors
- Sarah Cannon Research Institute, Nashville
- Vanderbilt Ingram Cancer Center, Nashville
Се регрутираФаза 1/2
Возраст 18 и постари · Сите полови · Ажурирано 17.8.2026 · NCT05919264A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
- Henry-Joyce Cancer Clinic, Nashville
Се регрутираФаза 2
Возраст 18 и постари · Мажи · Ажурирано 17.8.2026 · NCT06842498Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)
- Sarah Cannon Research, Nashville
Се регрутираФаза 1
Возраст од 18 до 100 · Мажи · Ажурирано 13.8.2026 · NCT05519449Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
- Tennessee Oncology PLLC, Nashville
Се регрутираФаза 1/2
Возраст 18 и постари · Сите полови · Ажурирано 30.7.2026 · NCT07288359PSMA PET Combined With MRI for the Detection of PCa
- The Conrad Pearson Clinic, Germantown
- Urology Associates of Nashville, Nashville
Се регрутираФаза 3Добредојдени се здрави волонтери
Возраст 18 и постари · Мажи · Ажурирано 23.7.2026 · NCT07052214Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
- Investigative Site #102, Nashville
Се регрутираФаза 1
Возраст 18 и постари · Сите полови · Ажурирано 23.7.2026 · NCT06545942Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response
- Vanderbilt University/Ingram Cancer Center, Nashville
Се регрутираФаза 3
Возраст 18 и постари · Мажи · Ажурирано 14.7.2026 · NCT06592924Study Evaluating the Safety, Tolerability, and Efficacy of Xaluritamig in Combination With Androgen Receptor Pathway Inhibitors in Participants With Metastatic Hormone-sensitive Prostate Cancer
- Sarah Cannon Research Institute, Nashville
Се регрутираФаза 1
Возраст 18 и постари · Мажи · Ажурирано 2.7.2026 · NCT07140900International Registry for Men With Advanced Prostate Cancer (IRONMAN)
- Memphis VA Medical Center, Memphis
- Baptist Clinical Research Institute, Memphis
Се регрутираНабљудувачка студија
Возраст 21 и постари · Мажи · Ажурирано 22.5.2026 · NCT03151629Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
- Sarah Cannon Research Institute, Nashville
Се регрутираФаза 1/2
Возраст 18 и постари · Сите полови · Ажурирано 6.5.2026 · NCT06239194A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
- Sarah Cannon Research Institute (SCRI) Oncology Partners, Nashville
- Vanderbilt University Medical Center, Nashville
Се регрутираФаза 1
Возраст 18 и постари · Сите полови · Ажурирано 13.2.2026 · NCT06778863A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer
- Urology Associates PC, Nashville
Се регрутираФаза 1
Возраст 18 и постари · Мажи · Ажурирано 4.2.2026 · NCT04729114Од ClinicalTrials.gov, податоци преземени 6.10.2026. Секоја студија ги поставува своите услови за вклучување; тимот на студијата одлучува кој може да учествува.